EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Experiences of an inpatient penicillin allergy de-labelling pathway: capturing the patient voice

Neil Powell iD, Mathew Upton iD, Bridie Kent, Jonathan Sandoe iD, Sarah Tonkin-Crine iD

JAC-Antimicrobial Resistance · 28.12.2023 · 6 (1)

DOI: 10.1093/jacamr/dlae020 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAC-Antimicrobial Resistance, online erschienen am 09.02.2024. Verfasst von Neil Powell und 4 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacy Department, Royal Cornwall Hospital, Truro TR1 3LJ, UK. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: HEE/NIHR ICA Programme Clinical Doctoral Research Fellowship.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Non-allergist-delivered penicillin allergy de-labelling (PADL) is supported by UK and other national guidelines but is not yet routine practice in UK hospitals. Those who have undergone PADL report high rates of acceptance, but it is unknown why some continue to avoid penicillin, and why some decline testing.

Objectives

To explore the experiences of patients recently approached for penicillin allergy (penA) assessment and de-label by non-allergists in a UK hospital to determine the barriers and enablers to patient acceptance of PADL.

Methods

Qualitative study using semi-structured interviews with patients who were penA assessed and de-labelled during an inpatient stay between November 2022 and January 2023. Thematic analysis was used to analyse the data.

Results

Nineteen patients were interviewed. Patients were largely unaware of the negative impact of penA on their healthcare. Patients had differing views on challenging their penA status while they were acutely unwell, some agreeing that it is the right time to test and others not. Patients declined testing because they felt they were at higher potential risk because they were older or had multiple comorbidities. Some patients who declined testing felt they would have been persuaded if they had received a better explanation of the risks and benefits of PADL.

Conclusions

Patients who were successfully de-labelled were positive about the experience. Those who declined testing did so for a variety of reasons including frailty/comorbidities or a fear of testing whilst unwell. Patients highlighted the importance of good communication about the personalized risks and benefits of testing.

Autor:innen und Institutionen

  • Pharmacy Department, Royal Cornwall Hospital, Truro TR1 3LJ, UK.
  • School of Biomedical Sciences, University of Plymouth, Plymouth PL4 8AA, UK.
  • School of Nursing and Midwifery, University of Plymouth, Plymouth, UK.
  • Leeds Institute of Medical Research, University of Leeds, Leeds, UK.
  • Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.

ORCID-Profile: Neil Powell, Mathew Upton, Jonathan Sandoe, Sarah Tonkin-Crine

Förderung

  • HEE/NIHR ICA Programme Clinical Doctoral Research Fellowship

Zitieren

APA

Powell, N., Upton, M., Kent, B., Sandoe, J., & Tonkin-Crine, S. (2023). Experiences of an inpatient penicillin allergy de-labelling pathway: capturing the patient voice. JAC-Antimicrobial Resistance, 6(1). https://doi.org/10.1093/jacamr/dlae020

Vancouver

Powell N, Upton M, Kent B, Sandoe J, Tonkin-Crine S. Experiences of an inpatient penicillin allergy de-labelling pathway: capturing the patient voice. JAC-Antimicrobial Resistance. 2023;6(1). doi:10.1093/jacamr/dlae020

BibTeX
@article{Powell2023,
  author = {Powell, Neil and Upton, Mathew and Kent, Bridie and Sandoe, Jonathan and Tonkin-Crine, Sarah},
  title = {Experiences of an inpatient penicillin allergy de-labelling pathway: capturing the patient voice},
  journal = {JAC-Antimicrobial Resistance},
  year = {2023},
  volume = {6},
  number = {1},
  doi = {10.1093/jacamr/dlae020}
}
Kostenlos starten →